An Oral Galectin Inhibitor in COVID-19-A Phase II Randomized Controlled Trial.

ABSTRACT:

Background

SARS-CoV-2 vaccines play an important role in reducing disease severity, hospitalization, and death, although they failed to prevent the transmission of SARS-CoV-2 variants. Therefore, an effective inhibitor of galectin-3 (Gal-3) could be used to treat and prevent the transmission of COVID-19. ProLectin-M (PL-M), a Gal-3 antagonist, was shown to interact with Gal-3 and thereby prevent cellular entry of SARS-CoV-2 in previous studies.

Aim

The present study aimed to further evaluate the therapeutic effect of PL-M tablets in 34 subjects with COVID-19.

Methods

The efficacy of PL-M was evaluated in a randomized, double-blind, placebo-controlled clinical study in patients with mild to moderately severe COVID-19. Primary endpoints included changes in the absolute

SUBMITTER: Sigamani A 

PROVIDER: S-EPMC10140888 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature